Rhumbline Advisers purchased a new stake in shares of Avrobio Inc (NASDAQ:AVRO) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 13,422 shares of the company’s stock, valued at approximately $296,000.
Other hedge funds have also recently added to or reduced their stakes in the company. TIAA CREF Investment Management LLC purchased a new stake in shares of Avrobio during the third quarter valued at about $425,000. New Leaf Venture Partners L.L.C. lifted its position in shares of Avrobio by 25.1% during the fourth quarter. New Leaf Venture Partners L.L.C. now owns 215,550 shares of the company’s stock valued at $3,589,000 after buying an additional 43,200 shares during the last quarter. Bank of New York Mellon Corp lifted its position in shares of Avrobio by 60.6% during the fourth quarter. Bank of New York Mellon Corp now owns 25,937 shares of the company’s stock valued at $431,000 after buying an additional 9,782 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Avrobio by 374.5% during the third quarter. Vanguard Group Inc. now owns 246,738 shares of the company’s stock valued at $12,798,000 after buying an additional 194,738 shares during the last quarter. Finally, Aisling Capital Management LP purchased a new stake in shares of Avrobio during the fourth quarter valued at about $12,271,000. 71.14% of the stock is owned by institutional investors and hedge funds.
Several equities analysts recently commented on AVRO shares. HC Wainwright set a $40.00 price objective on shares of Avrobio and gave the company a “buy” rating in a research report on Tuesday, May 14th. Cowen reaffirmed a “buy” rating on shares of Avrobio in a research report on Tuesday, May 14th. Janney Montgomery Scott started coverage on shares of Avrobio in a research report on Friday, April 5th. They issued a “buy” rating and a $24.42 price objective for the company. Finally, Zacks Investment Research lowered shares of Avrobio from a “hold” rating to a “sell” rating in a research report on Wednesday, February 20th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $31.06.
In other news, insider Geoffrey Mackay sold 14,000 shares of the firm’s stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $27.25, for a total transaction of $381,500.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Christopher Paige sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $25.72, for a total transaction of $257,200.00. The disclosure for this sale can be found here. Company insiders own 4.70% of the company’s stock.
Shares of Avrobio stock opened at $13.83 on Friday. Avrobio Inc has a 52 week low of $11.85 and a 52 week high of $53.70.
Avrobio (NASDAQ:AVRO) last posted its quarterly earnings results on Monday, May 13th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.01). On average, equities analysts expect that Avrobio Inc will post -2.93 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Rhumbline Advisers Invests $296,000 in Avrobio Inc (NASDAQ:AVRO) Stock” was originally posted by Macon Daily and is owned by of Macon Daily. If you are accessing this piece of content on another site, it was copied illegally and republished in violation of United States & international copyright laws. The legal version of this piece of content can be read at https://macondaily.com/2019/06/14/rhumbline-advisers-invests-296000-in-avrobio-inc-nasdaqavro-stock.html.
Avrobio Company Profile
AVROBIO, Inc, a clinical-stage gene therapy company, focuses on developing ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose in the United States. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene, which is defective in the target disease.
Featured Article: How to Trade Using Analysts Ratings
Want to see what other hedge funds are holding AVRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Avrobio Inc (NASDAQ:AVRO).
Receive News & Ratings for Avrobio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avrobio and related companies with MarketBeat.com's FREE daily email newsletter.